Spots Global Cancer Trial Database for ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
Official Title: A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 (Zibotentan) Plus Carboplatin and Paclitaxel or Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Study ID: NCT00929162
Study Description
Brief Summary: The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Research Site, Berlin, , Germany
Research Site, Dresden, , Germany
Research Site, Dusseldorf, , Germany
Research Site, Essen, , Germany
Research Site, Karlsruhe, , Germany
Research Site, Kassel, , Germany
Research Site, Kiel, , Germany
Research Site, Lich, , Germany
Research Site, Magdeburg, , Germany
Research Site, Marburg, , Germany
Research Site, Munchen, , Germany
Research Site, Rostock, , Germany
Research Site, Wiesbaden, , Germany
Research Site, Milano, MI, Italy
Research Site, Perugia, PG, Italy
Research Site, Aviano, PN, Italy
Research Site, Campobasso, , Italy
Research Site, Modena, , Italy
Research Site, Napoli, , Italy
Research Site, Roma, , Italy
Contact Details
Name: Tom Morris
Affiliation: AstraZeneca, Alderley Park
Role: STUDY_DIRECTOR
Name: Ian Thomas
Affiliation: AstraZeneca, Alderley Park
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
